IMPAX LABORATORIES, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 30, 2015 2.00% Convertible Senior Notes due 2022Indenture • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 13th, 2018 Company Industry JurisdictionINDENTURE dated as of June 30, 2015 between IMPAX LABORATORIES, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionThis Indemnification and Advancement Agreement (“Agreement”) is made as of [ ], 2018 by and between Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 June 26, 2015Warrant Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMay 7th, 2018 Company IndustryThe purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Impax Laboratories, Inc. (“Company”) to Royal Bank of Canada (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 June 25, 2015Base Call Option Transaction • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations
Contract Type FiledApril 13th, 2018 Company IndustryThe purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Royal Bank of Canada (“Dealer”) and Impax Laboratories, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
FORM OF AMNEAL PHARMACEUTICALS LLC THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of [ ]Limited Liability Company Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionThis THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of [ ], is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
TAX RECEIVABLE AGREEMENT by and among AMNEAL PHARMACEUTICALS, INC. AMNEAL PHARMACEUTICALS LLC and THE MEMBERS OF AMNEAL PHARMACEUTICALS LLC FROM TIME TO TIME PARTY HERETO Dated as of [●]Tax Receivable Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionThis TAX RECEIVABLE AGREEMENT (this “Agreement”), dated as of [●], is hereby entered into by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Amneal LLC”) and each of the Members from time to time party hereto. Capitalized terms used but not otherwise defined herein have the respective meanings set forth in Section 1.1.
TERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, and JPMORGAN CHASE BANK, N.A., TRUIST...Term Loan Credit Agreement • November 14th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 14th, 2023 Company Industry JurisdictionTERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto from time to time and JPMORGAN CHASE BANK, N.A. (“JPM”), as administrative agent (in such capacity, and as further defined in Section 1.01, the “Administrative Agent”), and as collateral agent (in such capacity, and as further defined in Section 1.01, the “Collateral Agent”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 13th, 2018 Company Industry JurisdictionEMPLOYMENT AGREEMENT (“Agreement”), entered into as of December 12, 2012 (the “Effective Date”), by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Bryan M. Reasons (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 6th, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledSeptember 6th, 2022 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is entered into as of September 1, 2022, by and between Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) and Gustavo Pesquin (the “Executive” and, collectively the “Parties”).
AMENDMENT NO. 1 TO REVOLVING CREDIT AGREEMENT AND AMENDMENT NO. 1 TO COLLATERAL AGREEMENTRevolving Credit Agreement • November 14th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 14th, 2023 Company Industry JurisdictionREVOLVING CREDIT AGREEMENT, dated as of June 2, 2022 (as amended by Amendment No. 1 and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto from time to time and TRUIST BANK (“Truist Bank”), as administrative agent (in such capacity, and as further defined in Section 1.01, the “Administrative Agent”), and as collateral agent (in such capacity, and as further defined in Section 1.01, the “Collateral Agent”).
Term Sheet Amneal Pharmaceuticals, Inc.Term Sheet • October 17th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 17th, 2023 Company Industry JurisdictionThis Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group Representative1, on behalf of the Amneal Legacy Group. Each of Old PubCo and Opco may be referred to herein as a “Party” and collectively as the “Parties”.
TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, each other Grantor party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral AgentTerm Loan Guarantee and Collateral Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionTERM LOAN GUARANTEE AND COLLATERAL AGREEMENT dated as of May 4, 2018 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), among AMNEAL PHARMACEUTICALS LLC (the “Borrower”) and each other party identified as a “Grantor” on the signature pages hereto (together with any other entity that may become a party hereto as a Grantor as provided herein, each a “Grantor” and, collectively, the “Grantors”), and JPMORGAN CHASE BANK, N.A. (“JPM”), as Administrative Agent for the Lenders under the Credit Agreement referred to below (in such capacity, the “Administrative Agent”) and as Collateral Agent for the Secured Parties (as defined below) (in such capacity, the “Collateral Agent”).
ContractRevolving Credit and Term Loan Agreement • November 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 9th, 2023 Company Industry Jurisdiction
MEMORANDUM OF UNDERSTANDINGMemorandum of Understanding • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledApril 13th, 2018 Company Industry JurisdictionTHIS MEMORANDUM OF UNDERSTANDING (“MOU”), is made and entered into as of the 16th day of December, 2017 (the “Effective Date”), by and among Amneal Pharmaceuticals LLC (the “Company”), Paul M. Bisaro (“Bisaro”), Impax Laboratories, Inc. (“Impax”), Amneal Holdings, LLC (“Amneal Holdings”) (solely with respect to and in connection with its obligations set forth in Paragraph 1 of this MOU) and Atlas Holdings, Inc. (“Atlas”). The Company, Impax, Bisaro and Atlas may be referred to herein individually as a “party” and collectively as the “parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of May 4, 2018 (the “Effective Date”), by and between Amneal Pharmaceuticals, Inc. (“Amneal”) and Paul M. Bisaro (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2021 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledMay 7th, 2021 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is entered into as of July 29, 2020, by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Nikita Shah (the “Executive” and, collectively with the Company, the “Parties”).
FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionFIRST SUPPLEMENTAL INDENTURE, dated as of November 6, 2017 (this “First Supplemental Indenture”), to the Indenture dated as of June 30, 2015 (the “Indenture”) between Impax Laboratories, Inc. (the “Company”), a Delaware corporation, and Wilmington Trust, National Association, a national banking association, as Trustee (the “Trustee”). Each term used herein which is defined in the Indenture has the meaning assigned to such term in the Indenture unless otherwise specifically defined herein, in which case the definition set forth herein shall govern.
FORM OF LETTER AGREEMENTPromissory Note and Collateral Agreement • August 5th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 5th, 2019 Company Industry JurisdictionThis letter agreement (this “Letter Agreement”) is to confirm the mutual understanding among Credit Suisse AG, acting through its New York Branch (the “Lender”), Amneal Pharmaceuticals LLC (the “Company”), Amneal Pharmaceuticals, Inc. (“Amneal”) and __________ (the “Borrower”) with respect to the pledge (the “Pledge”) by the Borrower to the Lender (itself or through one of its affiliates, any such affiliate being treated as the Lender for purposes of this Letter Agreement) of, initially, _________ Units of the Company (the “Units”) and an equal number of shares of Class B Common Stock of Amneal (the “Class B Shares”), in each case pursuant to a Promissory Note and Collateral Agreement dated as of ____________ between the Borrower and the Lender (as amended, supplemented or modified from time to time, the “Loan Agreement”) and certain transactions related thereto. The Pledge will be made in favor of the Lender (the Units and Class B Shares that are so pledged at any time, the “Pledged S
BUSINESS COMBINATION AGREEMENT Dated as of October 17, 2017 By and Among IMPAX LABORATORIES, INC., ATLAS HOLDINGS, INC., K2 MERGER SUB CORPORATION and AMNEAL PHARMACEUTICALS LLCBusiness Combination Agreement • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 13th, 2018 Company Industry JurisdictionThis BUSINESS COMBINATION AGREEMENT (this “Agreement”), dated as of October 17, 2017, is by and among Impax Laboratories, Inc., a Delaware corporation (“Impax”), Atlas Holdings, Inc., a Delaware corporation and a wholly-owned Subsidiary of Impax (“Holdco”), K2 Merger Sub Corporation, a Delaware corporation and a wholly-owned Subsidiary of Holdco (“Merger Sub”) and Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Amneal”).
TERMINATION AGREEMENT dated as of May 7, 2018 Between IMPAX LABORATORIES, LLC (f/k/a IMPAX LABORATORIES, INC.) and ROYAL BANK OF CANADATermination Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionTHIS TERMINATION AGREEMENT (this “Agreement”) with respect to the Call Spread Confirmations (as defined below) is made as of May 7, 2018, between Impax Laboratories, LLC (formerly known as Impax Laboratories, Inc.) (“Company”) and Royal Bank of Canada (“Dealer”).
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT DATED AS OF NOVEMBER 7, 2023 BY AND AMONG AMNEAL GROUP (AS DEFINED HEREIN), AMNEAL PHARMACEUTICALS LLC, AMNEAL INTERMEDIATE INC. AND AMNEAL PHARMACEUTICALS, INC.Stockholders Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 8th, 2023 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (as may be further amended from time to time in accordance with the terms hereof, this “Agreement”), is entered into as of November 7, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (formerly known as Amneal NewCo Inc.) (the “Company”), Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc. and Atlas Holdings, Inc.), a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Opco”) and each other Person set forth on the signature pages hereto (collectively, the “Amneal Group” and individually each, an “Amneal Group Member”).
MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED FEBRUARY 6, 2018Employment Agreement • May 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMay 9th, 2023 Company IndustryThis Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Andrew Boyer (the “Executive” and, collectively with Amneal, the “Parties”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL NEWCO INC. AND AMNEAL MERGER SUB 1 INC. DATED AS OF NOVEMBER 7, 2023Merger Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 8th, 2023 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER (the “Agreement”) is entered into as of 12:01 a.m. Eastern Time on November 7, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal NewCo Inc., a Delaware corporation and a direct, wholly owned subsidiary of Old PubCo (“New PubCo”), and Amneal Merger Sub 1 Inc., a Delaware corporation and a direct, wholly owned subsidiary of New PubCo (“Merger Sub 1”) (each a “Party” and collectively the “Parties”).
IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE COMMISSION RULES, CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. BRACKETS WITH ASTERISKS...Share Purchase Agreement • March 1st, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 1st, 2022 Company Industry
AMNEAL PHARMACEUTICALS LLC FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 7, 2023Limited Liability Company Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 8th, 2023 Company Industry JurisdictionThis FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of November 7, 2023, is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
EQUITY PURCHASE AGREEMENT among STEVE SHIRLEY BUSINESS TRUST, JERRY SHIRLEY BUSINESS TRUST, JERRY BRIAN SHIRLEY BUSINESS TRUST, DARREN THOMAS SHIRLEY BUSINESS TRUST, TROY MIZELL, DARRELL CALVERT, DIXON-SHANE LLC D/B/A R&S NORTHEAST LLC, AVKARE, INC....Equity Purchase Agreement • December 10th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 10th, 2019 Company Industry JurisdictionThis Equity Purchase Agreement (this “Agreement”), dated as of December 10, 2019, is entered into among the Jerry Brian Shirley Business Trust (the “JBS Trust”), the Darren Thomas Shirley Business Trust (the “DTS Trust”), the Steve Shirley Business Trust (the “SS Trust”), the Jerry Shirley Business Trust (the “JS Trust”, and collectively with the JBS Trust, the DTS Trust, the SS Trust, the “Trusts”), Troy Mizell, a resident of the State of Tennessee (“Mizell”), Darrell Calvert, a resident of the Commonwealth of Kentucky (“Calvert”) (the Trusts, Mizell and Calvert each being a “Seller” and collectively being the “Sellers”), AvKARE, Inc., a Tennessee corporation (“AvKARE”), Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S Northeast”, and together with AvKARE, each a “Company” and collectively, the “Companies”), and Rondo Acquisition LLC, a Delaware limited liability company (“Buyer”). Steve Shirley also joins this Agreement in his capacity as the Selle
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 June 26, 2015Additional Call Option Transaction • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations
Contract Type FiledApril 13th, 2018 Company IndustryThe purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Royal Bank of Canada (“Dealer”) and Impax Laboratories, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF AMNEAL PHARMACEUTICALS LLCLimited Liability Company Agreement • March 1st, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 1st, 2019 Company Industry JurisdictionThis Amendment No. 1 to the Third Amended and Restated Limited Liability Company Agreement of Amneal Pharmaceuticals LLC (this “Amendment”), dated as of February 14, 2019, with effect as of May 4, 2018, is entered into by and among Amneal Pharmaceuticals LLC (the “Company”), the Manager and the Members set forth on the signature pages hereto.
MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED MARCH 11, 2020Employment Agreement • May 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMay 9th, 2023 Company IndustryThis Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Anastasios G. Konidaris (the “Executive” and, collectively with Amneal, the “Parties”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL PHARMACEUTICALS LLC AND AMNEAL MERGER SUB 2 LLC DATED AS OF NOVEMBER 7, 2023Merger Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 8th, 2023 Company Industry JurisdictionThis FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of November 7, 2023, is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
AMNEAL PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionAmneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in this Stock Option Grant Notice (the “Grant Notice”), the Stock Option Agreement attached hereto as Exhibit A (the “Agreement”), the Plan and the special provisions for Participant’s country of residence, if any, attached hereto as Exhibit B (the “Foreign Appendix”), each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.
Re: Notice of Employment Termination Dear Todd:Employment Agreement • May 11th, 2020 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMay 11th, 2020 Company IndustryAmneal Pharmaceuticals, Inc. (together, "Amneal") dated January 21, 2019 (your "Employment Agreement"). Your status as an officer of Amneal ends effective as of today, March 11, 2020, and you are hereby relieved of all of your duties and responsibilities related to your officer position. Your employment with Amneal will continue until March 31, 2020 (the "Termination Date"), and this letter constitutes notice under Section 4.1.6 of your Employment Agreement that your employment with Amneal will terminate without cause effective as of the Termination Date.
PURCHASE AND SALE AGREEMENT by and among AMNEAL PHARMACEUTICALS LLC, GEMINI LABORATORIES, LLC, THE PERSONS SIGNATORY HERETO AS SELLERS AND THE SELLERS’ REPRESENTATIVE Dated as of May 7, 2018Purchase and Sale Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 7th, 2018 Company Industry JurisdictionThis Purchase and Sale Agreement, dated as of May 7, 2018 (this “Agreement”), by and among (i) Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Buyer”), (ii) Gemini Laboratories, LLC, a Delaware limited liability company (the “Acquired Company” or “Gemini”), (iii) each of the persons designated on the signature pages hereto as Sellers (each a “Seller” and, collectively, the “Sellers”), and (iv) Vikram Patel, solely in his capacity as the Sellers’ Representative.
Amendment No. 1 to the Second Amended and Restated Stockholders AgreementStockholders Agreement • August 5th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 5th, 2019 Company Industry JurisdictionThis Amendment No. 1 (this “Amendment”) to the Second Amended and Restated Stockholders Agreement dated as of December 16, 2017 (the “Agreement”), by and among Amneal Pharmaceuticals Holding Company, LLC, a Delaware limited liability company, AP Class D Member, LLC, a Delaware limited liability company, AP Class E Member, LLC, a Delaware limited liability company, AH PPU Management, LLC, a Delaware limited liability company, and Amneal Pharmaceuticals, Inc. (which was previously known as Atlas Holdings, Inc.), a Delaware corporation, is entered into as of this 2nd day of August, 2019. Capitalized terms used in this Amendment and not otherwise defined shall have the meanings ascribed to them in the Agreement.
ASSET PURCHASE AGREEMENT AMONG SAOL INTERNATIONAL LIMITED, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., SAOL INTERNATIONAL RESEARCH LIMITED, SAOL INTERNATIONAL DEVELOPMENT LIMITED, EMERALD INTERNATIONAL LIMITED, EMERALD THERAPEUTICS...Asset Purchase Agreement • January 5th, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 5th, 2022 Company Industry JurisdictionThis Asset Purchase Agreement (this “Agreement”) is entered into as of December 30, 2021, by and among Saol International Limited, a Bermuda limited company (“SIL”), Saol Therapeutics Research Limited, an Irish limited company (“STRL”), Saol Therapeutics Inc., a Delaware corporation (“STI”), Saol International Research Limited, a Bermuda limited company (“SIRL”), Saol International Development Limited, a Bermuda limited company (“SIDL”), Emerald International Limited, a Bermuda limited company (“Emerald”), Emerald Therapeutics Research Limited, an Irish limited company (“ETRL” and, collectively with SIL, STRL, STI, SIRL, SIDL and Emerald, “Sellers” and each, individually, a “Seller”), and Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Buyer”). Buyer and Sellers are each referred to herein as a “Party” and collectively herein as the “Parties.”